Please ensure Javascript is enabled for purposes of website accessibility

Is Moderna Stock a Buy After Plunging More Than 35%?

By Keith Speights – Oct 13, 2021 at 5:52AM

Key Points

  • Moderna's shares have plunged due to several reasons.
  • The company's long-term prospects still appear to be strong.
  • The key problem with buying the stock, though, is its steep valuation even after the recent sell-off.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Some of the reasons behind the vaccine stock's sell-off appear to be much ado about nothing. But not all of them.

Throughout most of 2020 and 2021, it seemed as if Moderna (MRNA -1.27%) could do no wrong. The company won multiple supply deals for its COVID-19 vaccine. Moderna's revenue and profits skyrocketed. And so did its share price.

The last couple of months have been much different. There's been plenty of bad news for Moderna. Most of the summer's gains have evaporated. However, this major pullback has prompted some investors to wonder if the vaccine stock has fallen more than is warranted. Is Moderna stock a buy after plunging more than 35%? 

Two scientists with one holding a vaccine vial.

Image source: Getty Images.

Behind the decline

Anytime a stock drops precipitously, the most important step for investors is to understand the reasons behind the decline. In Moderna's case, there are at least three primary factors at work.

Arguably the biggest reason for the stock sinking over the last two months is that investors worried that Moderna's valuation got out of hand. At one point, Moderna's market cap approached $200 billion. That level is much higher than several other drugmakers with more revenue and many more products on the market than Moderna.

A second cause for Moderna's shares falling relates to safety concerns. In August, the European Medicines Agency began investigating potential adverse side effects reported in individuals receiving Moderna's COVID-19 vaccine. 

Last week, four European countries suspended or discouraged the use of the vaccine in some younger individuals. These actions were taken after a study conducted by Sweden's health agency linked Moderna's vaccine to rare heart inflammation issues that occur primarily in younger men. 

Some investors also panicked after Merck and Ridgeback Biotherapeutics reported positive results from a late-stage study of a COVID-19 pill. The thought was that vaccine sales could be negatively impacted if a safe, effective, and convenient pill becomes available that can significantly reduce the likelihood of developing severe COVID-19.

Looking on the bright side

There's a pretty good argument to be made that the sell-off of Moderna stock was overdone in most of those cases. For example, the safety issues associated with the company's COVID-19 vaccine aren't likely to hurt Moderna very much financially. The issues are very rare. More importantly, Moderna already has major supply deals in place for 2022 and beyond.

Merck's COVID-19 pill shouldn't matter all that much to Moderna's prospects, either. Governments around the world are highly unlikely to reduce their vaccination efforts just because an oral COVID-19 therapy is available (assuming Merck wins authorizations for its antiviral pill.) 

As for valuation concerns, Moderna's long-term opportunities remain as compelling now as they were when its stock was setting record highs. The company continues to anticipate that COVID-19 boosters will be needed, likely on an annual basis. Moderna is still a leader in developing new vaccines that target specific coronavirus variants.

The company's pipeline is even stronger than ever. Moderna plans to soon advance its cytomegalovirus vaccine into late-stage testing. The company's respiratory syncytial virus (RSV) vaccine should move into phase 2/3 clinical studies soon. It's testing a messenger RNA (mRNA) flu vaccine -- a key step toward achieving the goal of developing a combination COVID-19/flu vaccine. 

Two takes

I have two takes on Moderna. On the one hand, I think the company's mRNA platform could lead to multiple blockbuster vaccines and therapies over the coming years. I also believe there's a pretty good chance that Moderna will be able to generate strong recurring revenue from its COVID-19 vaccine for years to come.

On the other hand, I agree with those who feel that Moderna's valuation rose too much too quickly. I didn't have a big problem when the company's market cap stood at $70 billion or even $80 billion. However, even after the recent decline, my view is that Moderna is still valued too high considering the uncertainty about how often COVID-19 boosters might be needed in the future.

I continue to like Moderna the company. But I'll remain on the sidelines for now with Moderna the stock.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna Inc. Stock Quote
Moderna Inc.
$173.15 (-1.27%) $-2.23
Merck & Co. Stock Quote
Merck & Co.
$108.84 (0.36%) $0.39

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.